Alkermes Scheduled to Discuss Q1 Financial Performance Soon
Alkermes to Present First Quarter Results on May 1
Alkermes plc (Nasdaq: ALKS) is set to hold a significant conference call on May 1, where they will discuss their financial results for the first quarter of the year. This event is anticipated to provide crucial insights into the company's performance and future strategies.
Conference Call and Webcast Details
The conference call will start at 8:00 a.m. ET, which corresponds to 1:00 p.m. BST. Interested parties can participate in the call by dialing the U.S. number +1 877 407 2988 or the international number +1 201 389 0923. The call will also be streamed live via a webcast, details of which can be found on the Investors section of Alkermes' corporate website.
Access to Webcast Replay
For those unable to join the live call, Alkermes will provide a replay of the webcast about two hours after the conclusion of the event. This replay will be accessible through Alkermes' website, ensuring that stakeholders can stay informed about the company's developments.
Understanding Alkermes plc
Alkermes plc is a renowned global biopharmaceutical company dedicated to advancing innovative medicines in the neuroscience sector. The company's offerings include proprietary products aimed at treating alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Additionally, Alkermes is actively involved in the development of clinical and preclinical candidates aimed at neurological disorders like narcolepsy and idiopathic hypersomnia.
Headquarters and Operations
Headquartered in Ireland, Alkermes maintains a robust research and development presence with facilities located in Massachusetts and a manufacturing center in Ohio. This diverse operational footprint supports the company’s commitment to producing effective therapies while advancing groundbreaking research in its field.
Contact Information
For further inquiries, contact Jamie Constantine from Investor Relations at +1 781 873 2402. Alkermes remains committed to transparency and communication with its investors and stakeholders.
Frequently Asked Questions
When will Alkermes report its first quarter financial results?
Alkermes is scheduled to report its first quarter financial results on May 1.
How can I access the conference call?
You can access the conference call by dialing +1 877 407 2988 for U.S. callers or +1 201 389 0923 for international callers.
Is there a way to listen to the replay of the call?
Yes, a replay of the webcast will be available two hours after the event on Alkermes' website.
What therapeutic areas does Alkermes focus on?
Alkermes focuses on developing treatments for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, among others.
Where is Alkermes headquartered?
Alkermes is headquartered in Ireland, with additional facilities in Massachusetts and Ohio.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.